Table 1.
Baseline characteristics of the patients who had two measurements of NT-BNP-76 by treatment group
| Characteristic | CKD 3–4 (n=49) | Dialysis (n=102) | Transplant (n=71) | P Value |
|---|---|---|---|---|
| Age (yr) | 67.1±11.2 | 62.6±14.3 | 52.8±10.7 | <0.001 |
| Men | 37 (76) | 60 (59) | 46 (63) | 0.13 |
| Diabetes | 21 (43) | 20 (20) | 8 (11) | <0.001 |
| Cardiovascular disease | 19 (39) | 32 (31) | 9 (13) | 0.003 |
| Coronary artery disease | 15 (31) | 24 (24) | 4 (6) | 0.001 |
| Heart failure | 8 (16) | 19 (19) | 1 (1) | 0.002 |
| Cerebrovascular disease | 1 (2) | 7 (7) | 2 (3) | 0.29 |
| Peripheral vascular disease | 8 (16) | 16 (16) | 3 (4) | 0.05 |
| Smoking | 30 (61) | 55(54) | 36 (51) | 0.52 |
| Systolic BP (mmHg) | 132±21 | 145±24 | 129±14 | <0.001 |
| Diastolic BP (mmHg) | 76±9 | 78±13 | 77±6 | 0.46 |
| BMI (kg/m2) | 27.3 (24.2–31.8) | 24.2 (21.8–27.4) | 26.5 (23.3–29.8) | <0.001 |
| Antiplatelet agent | 24 (49) | 39 (38) | 15 (21) | <0.01 |
| RAS blockade | 33 (67) | 39 (38) | 41 (58) | 0.001 |
| Statin | 26 (53) | 46 (45) | 44 (62) | 0.09 |
| β-Blocker | 17 (35) | 35 (34) | 35 (49) | 0.11 |
| eGFR (ml/min per 1.73 m2) | 24±11 | — | 35±16 | <0.001 |
| Hemoglobin (g/dl) | 12.3±1.6 | 12.1±1.2 | 12.9±1.9 | 0.003 |
| C-reactive protein (mg/L) | 3.8 (1.8–7.6) | 5.0 (3.0–11.8) | 1.6 (0.6–4.6) | <0.001 |
| Albumin (g/dl) | 4.01±0.39 | 3.76±0.41 | 4.12±0.32 | <0.001 |
| cTnT-positive (sample 1) | 9 (19) | 48 (47) | 6 (8) | <0.001 |
| cTnT-positive (sample 2) | 10 (21) | 59 (58) | 8 (11) | <0.001 |
Results are similar for patients with two measurements of 32–amino acid BNP (data not shown). Values expressed with a plus/minus sign are the mean±SD; all other values are the number (percentage) of patients. NT-BNP-76, N-terminal end B-type natriuretic peptide; BMI, body mass index; RAS, renin-angiotensin system; cTnT-positive, cardiac troponin T≥0.04 ng/ml.